Enovis Corporation

Sep 22, 2026

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

Enovis has become the first industry partner to sponsor multiple registries within the AAOS Registry Program, expanding its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry. This collaboration aims to enhance data collection and improve patient care in shoulder and elbow treatments. The initiative is expected to provide valuable insights into treatment patterns and outcomes.

eCential Robotics Announces Binding Offer from Enovis

eCential Robotics has announced a binding offer from Enovis Corporation to acquire the company. This acquisition aims to enhance Enovis' technology portfolio with eCential's robotic solutions, which are already FDA-cleared for spine surgery. The transaction is expected to close in Q4 2026, pending regulatory approvals. Both companies express optimism about the potential for improved surgical outcomes and innovation.

Sep 1, 2026

▼ -16.5%on this newsshared move

Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics

Enovis Corporation has announced a binding offer to acquire eCential Robotics for €155 million, enhancing its surgical robotics capabilities. This acquisition aims to improve surgical precision and streamline workflows, with a center of excellence planned in Grenoble, France. The deal is expected to close by year-end 2026, pending regulatory approvals.

Aug 31, 2026

▼ -16.5%on this newsshared move

Enovis to Participate in the 2026 Wells Fargo Healthcare Conference

Enovis Corporation announced its participation in the 2026 Wells Fargo Healthcare Conference, scheduled for September 8, 2026. CEO Damien McDonald and CFO Ben Berry will engage in a fireside chat at 1:30 p.m. Eastern Time. The event will be accessible via a live audio webcast on the company's website.

Enovis Announces Second Quarter 2026 Results

Enovis Corporation reported its second-quarter 2026 financial results, showcasing a 3% increase in net sales and an 8% growth in Reconstructive sales. The company reaffirmed its full-year guidance for revenue and adjusted EBITDA, indicating confidence in its operational improvements. However, it also acknowledged challenges, including a net loss and a decline in P&R sales.

Jul 17, 2026

Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

Enovis Corporation will host an investor conference call on August 6th, 2026, to discuss its second quarter financial results. The call will begin at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning. Investors can access the call via a dedicated link on the Enovis website.

Jul 13, 2026

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

Enovis Corporation has launched CT-RevitL, a next-generation laser therapy system for veterinary care in the U.S. This system enhances clinical performance and simplifies treatment delivery for veterinary teams. With a foundation of over 150 studies on photobiomodulation therapy, CT-RevitL aims to improve patient outcomes and support practice growth. It is now available in the U.S. with plans for international rollout.

Jun 8, 2026

Enovis Launches Spinamic Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

Enovis Corporation has launched the DonJoy Spinamic Hybrid Scoliosis Brace, designed to merge the corrective capabilities of traditional rigid braces with the comfort of dynamic options. The brace can be fitted in 10 sizes and utilizes an adjustable three-point pressure system to enhance wearability and compliance among adolescents with adolescent idiopathic scoliosis (AIS). Currently available in the U.S., the Spinamic brace aims to improve treatment outcomes while reducing the psychological burden often associated with traditional bracing methods. Enovis is also seeking regulatory clearance in additional markets worldwide.

Enovis Announces First Quarter 2026 Results

Enovis Corporation reported a 5% increase in first-quarter sales for 2026, driven by an 11% growth in Reconstructive sales. Despite a net loss of $8 million, the company reaffirmed its full-year financial guidance, highlighting confidence in its innovation-led strategy. The results reflect stable market conditions and successful new product introductions.

Apr 10, 2026

Enovis to Host First Quarter 2026 Results Conference Call on May 7th

Enovis Corporation will hold a conference call on May 7, 2026, to discuss its first quarter financial results. The call will be accessible via a live webcast and will include an earnings press release. Investors can participate by dialing in or accessing the webcast through the company's website.

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Corporation reported its financial results for Q4 and full year 2025, showing a 3% increase in Q4 net sales and a 7% increase for the full year. However, the company faced a substantial net loss of $1,182 million, largely due to a goodwill impairment charge. Looking ahead, Enovis expects revenue growth of 4-6% for 2026, with adjusted EBITDA projected between $425-435 million.

Feb 26, 2026

▲ +13.9%on this newsshared move

Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Corporation reported its financial results for Q4 and full year 2025, showing a 3% increase in net sales for Q4 and a 7% increase for the full year. However, the company faced a substantial net loss of $519 million in Q4 due to a goodwill impairment charge. Looking ahead, Enovis expects revenue growth of 4-6% for 2026, with adjusted EBITDA projected between $425-435 million.

Feb 3, 2026

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Enovis Corporation will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. The event will take place in Snowbird, Utah, showcasing Enovis's commitment to innovation in medical technology. The company focuses on developing solutions that improve patient outcomes and enhance surgical efficiency.

Jan 26, 2026

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th

Enovis Corporation will host an investor conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will start at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that day. Investors can access the live webcast through the Enovis website.

Jan 8, 2026

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Enovis Corporation (NYSE: ENOV) has announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will occur at 4:30 p.m. PST and will be accessible via a live audio webcast. Enovis is known for creating clinically differentiated medical solutions aimed at enhancing patient lives. The company emphasizes transparency by routinely sharing material information through various channels, including its Investor Relations website.

Jan 6, 2026

Enovis Appoints Oliver Engert as Chief Administrative Officer

Enovis Corporation has appointed Oliver Engert as Chief Administrative Officer, effective immediately. In this newly created role, Engert will focus on strategy development and operational efficiency to support the company's growth. CEO Damien McDonald expressed confidence in Engert's ability to drive success and improve patient care through his extensive experience.

Enovis Announces Third Quarter 2025 Results

Enovis Corporation reported its third-quarter financial results for 2025, showcasing a 9% increase in net sales year-over-year, reaching $549 million. Despite this growth, the company faced a substantial net loss of $571 million, primarily due to a non-cash goodwill impairment charge. The CEO emphasized a focus on strategic priorities for future growth, including operational excellence and innovation.

Oct 24, 2025

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

Enovis Corporation announced it will host a conference call and live webcast on November 6, 2025, to discuss its third quarter financial results. The company will also participate in various investor conferences. Investors can access the webcast and a replay on Enovis' website, enhancing transparency and communication.

Oct 8, 2025